News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Louisiana's Top Court Rules For Johnson & Johnson (JNJ) In Appeal Of Risperdal Suit


1/29/2014 8:04:55 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Johnson & Johnson won an appeal in Louisiana Supreme Court on Tuesday over its marketing of anti-psychotic drug Risperdal as the court overturned a ruling that would have imposed a $258 million penalty on the company. The ruling said that the Louisiana Attorney General, James Caldwell, failed to prove that Janssen Pharmaceutical Inc, part of J&J, violated state law when it misrepresented through off-label statements the potential risk of side effects of the drug. The Louisiana case was not part of a broader $2.2 billion settlement that J&J had made last fall with the U.S. Department of Justice regarding marketing practices for the drug.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Nasdaq
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES